Източници за „Хиперактивност и дефицит на вниманието при възрастни“

  1. Konofal E, Lecendreux M, Arnulf I, Mouren MC. Iron deficiency in children with attention-deficit/hyperactivity disorder. Archives of Pediatrics & Adolescent Medicine. 2004; 158:1113–1115
  2. Konofal E, Lecendreux M, Deron J, Marchand M, Cortese S, Zaïm M, Arnulf I. Effects of iron supplementation on attention deficit hyperactivity disorder in children. Pediatric Neurology. 2008.
  3. Calarge C, Farmer C, DiSilvestro R, Arnold LE. Serum ferritin and amphetamine response in youth with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology. 2010; 20:495–502.
  4. Bilici M, Yildirim F, Kandil S, Bekaroğlu M, Yildirmş S, Değer O, Aksu H. Double-blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2004; 28:181–190.
  5. Arnold LE, Bozzolo H, Hollway J, Cook A, DiSilvestro RA, Bozzolo DR, Williams C. Serum zinc correlates with parent-and teacher-rated inattention in children with attention-deficit/hyperactivity disorder. Journal of Child & Adolescent Psychopharmacology. 2005; 15:628–636.
  6. Arnold LE, DiSilvestro RA, Bozzolo D, Bozzolo H, Crowl L, Fernandez S, Joseph E. Zinc for attention-deficit/hyperactivity disorder: placebo-controlled double-blind pilot trial alone and combined with amphetamine. Journal of child and adolescent psychopharmacology. 2011; 21:1–19.
  7. Antalis CJ, Stevens LJ, Campbell M, Pazdro R, Ericson K, Burgess JR. Omega-3 fatty acid status in attention-deficit/hyperactivity disorder. Prostaglandins, leukotrienes and essential fatty acids. 2006; 75:299–308
  8. Dervola KS, Roberg BA, Wøien G, Bogen IL, Sandvik TH, Sagvolden T, Walaas SI. Marine omega-3 polyunsaturated fatty acids induce sex-specific changes in reinforcer-controlled behaviour and neurotransmitter metabolism in a spontaneously hypertensive rat model of ADHD. Behavioral and Brain Functions. 2012; 8:9081–1188
  9. Bloch MH, Qawasmi A. Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis. Journal of the American Academy of Child & Adolescent Psychiatry. 2011; 50:991–1000.
  10. Sonuga-Barke EJ, Brandeis D, Cortese S, Daley D, Ferrin M, Holtmann M, Sergeant J. Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. American Journal of Psychiatry. 2013; 170:275–289.
  11. Petkov VD, Yonkov D, Mosharoff A, Kambourova T, Alova L, Petkov VV, Todorov I. Effects of alcohol aqueous extract from Rhodiola rosea L. roots on learning and memory. Acta physiologica et pharmacologica Bulgarica. 1986; 12:3–16.
  12. Stancheva SL, Mosharrof A. Effect of the extract of rhodiola rosea L. on the content of the brain biogenic monoamines. Medecine Physiologie Comptes Rendus De L’Academie Bulgare Des Sciences. 1987; 40:85–87
  13. van Diermen D, Marston A, Bravo J, Reist M, Carrupt PA, Hostettmann K. Monoamine oxidase inhibition by Rhodiola rosea L. roots. Journal of Ethnopharmacology. 2009; 122:397–401.
  14. Panossian A, Wikman G, Sarris J. Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacy. Phytomedicine. 2010; 17:481–493.
  15. Darbinyan V, Kteyan A, Panossian A, Gabrielian E, Wikman G, Wagner H. Rhodiola rosea in stress induced fatigue–a double blind cross-over study of a standardized extract SHR-5 with a repeated low-dose regimen on the mental performance of healthy physicians during night duty. Phytomedicine. 2000; 7:365–371
  16. Shevtsov VA, Zholus BI, Shervarly VI, Vol’skij VB, Korovin YP, Khristich MP, Wikman G. A randomized trial of two different doses of a SHR-5 Rhodiola rosea extract versus placebo and control of capacity for mental work. Phytomedicine. 2003; 10:95–105.
  17. Yoshitake T, Yoshitake S, Kehr J. The Ginkgo biloba extract EGb 761® and its main constituent flavonoids and ginkgolides increase extracellular dopamine levels in the rat prefrontal cortex. British Journal of Pharmacology. 2010; 159:659–668
  18. Fehske CJ, Leuner K, Müller WE. Ginkgo biloba extract (EGb761®) influences monoaminergic neurotransmission via inhibition of NE uptake, but not MAO activity after chronic treatment. Pharmacological Research. 2009; 60:68–73.
  19. Diamond BJ, Bailey MR. Ginkgo biloba: Indications, mechanisms, and safety. Psychiatric Clinics of North America. 2013; 36:73–83.
  20. Niederhofer H. Ginkgo biloba treating patients with attention-deficit disorder. Phytotherapy Research. 2010; 24:26–27.
  21. van der Heijden KBV, Smits MG, Van Someren EJ, Ridderinkhof KR, Gunning WB. Effect of melatonin on sleep, behavior, and cognition in ADHD and chronic sleep-onset insomnia. Journal of the American Academy of Child and Adolescent Psychiatry. 2007; 46:233–241.
  22. Bendz LM, Scates AC. Melatonin treatment for insomnia in pediatric patients with attention-deficit/hyperactivity disorder. Annals of Pharmacotherapy. 2010; 44:185–191.
  23. Sharma A, Gerbarg PL, Brown RP. Non-Pharmacological Treatments for ADHD in Youth. Adolesc Psychiatry (Hilversum). 2015;5(2):84–95.